ArticleFrontiers in cellular and infection microbiology2026
Associations of probiotics combined with Tongli Gongxia Chinese medicine with intestinal barrier biomarkers and day 7 short-chain fatty acids in patients with severe acute pancreatitis.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe acute pancreatitis (SAP) is characterized by intestinal barrier dysfunction and altered short-chain fatty acid (SCFA) profiles, contributing to bacterial translocation and systemic complications. This study examined whether receipt of probiotics combined with Tongli Gongxia Chinese medicine was associated with intestinal barrier biomarker changes and day 7 fecal SCFA concentrations in SAP patients. Methods: This single-center retrospective cohort study included 240 SAP patients hospitalized between January 2019 and December 2024. After 1:1 propensity score matching, 200 patients (100 per group) were analyzed. The combination therapy group received multi-strain probiotics and Tongli Gongxia formula (Dachengqi Decoction) initiated within 72 hours of admission, plus standard therapy. The control group was restricted to patients receiving standard therapy alone during the corresponding early-treatment window. Primary outcomes were changes in four serum intestinal barrier biomarkers (diamine oxidase [DAO], D-lactate, lipopolysaccharide [LPS], and intestinal fatty acid-binding protein [I-FABP]) from baseline to day 7. Secondary outcomes included day 7 fecal SCFA concentrations, clinical outcomes, and safety events. Because baseline fecal SCFA samples were not available, SCFA analyses were interpreted as cross-sectional day 7 comparisons rather than treatment-induced changes. Results: Combination therapy was associated with greater reductions in barrier dysfunction biomarkers: ΔDAO -2.6 U/L (95% CI -3.8 to -1.4, p<0.001), ΔD-lactate -1.3 mmol/L (95% CI -1.9 to -0.7, p<0.001), ΔLPS -0.09 EU/mL (95% CI -0.13 to -0.05, p<0.001), and ΔI-FABP -216 pg/mL (95% CI -328 to -104, p<0.001). Day 7 SCFA concentrations were higher in the combination therapy group: total SCFAs 105.6 vs 85.0 μmol/g (p=0.001), including butyrate 14.6 vs 10.8 μmol/g (p=0.003). ICU stay was shorter by 2 days (11 vs 13 days, p=0.03). No probiotic-associated infections occurred. Diarrhea rates were similar (28% vs 18%, p=0.09). Conclusions: In this retrospective matched cohort, probiotics combined with Tongli Gongxia Chinese medicine were associated with greater improvement in intestinal barrier biomarkers, higher day 7 fecal SCFA concentrations, shorter ICU stay, and acceptable safety. These hypothesis-generating findings merit investigation in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.